Kristi J. Smock
No Rating Available
(Learn About Our Rating System)

Kristi J. Smock, MD

Languages spoken: English

  • Dr. Smock is a Professor in the Department of Pathology at the University of Utah. She completed her residency and fellowship training at the University of Utah and is board certified in Anatomic and Clinical Pathology and Hematopathology. She is Vice President and Chief Medical Director for the ARUP Laboratories Institute of Clinical and Experimental Pathology (R&D), leading research and development efforts across traditional laboratory medicine, genetics, and oncology and chairing the ARUP R&D Executive Committee.

    Dr. Smock’s primary clinical responsibilities are in coagulation laboratory medicine, and she is a Medical Director of the Hemostasis/Thrombosis Laboratory at ARUP, where she enjoys being involved in all aspects of the laboratory and providing clinical consultation on difficult coagulation cases. She has additional clinical service responsibilities in hematopathology, where she signs out peripheral smears, bone marrow cases and hematology tests.

    Dr. Smock enjoys the educational aspects of academic practice and previously served as the Pathology Residency Program Director at the University of Utah. She has chaired the Clinical Competency Committees for both the residency program and hematopathology fellowship. She received the Department's Outstanding Teaching Award in Clinical Pathology in 2010, 2013, and 2017. She serves on the University of Utah Alpha Omega Alpha medical honor society (AOA) Faculty Board of Directors with an emphasis on resident, fellow, and faculty engagement. In 2018, she received the William Roberts Award for Clinical Excellence in Laboratory Medicine, and in 2022, she received the Joseph A. Knight Award for Excellence in Education, from the University of Utah Department of Pathology. In 2016, Dr. Smock was named as an American Society for Clinical Pathology 40 Under Forty honoree, recognizing her as a leader in Pathology and Laboratory Medicine.

    Dr. Smock is an active member of several professional organizations and is current President of the North American Specialized Coagulation Laboratory Association (NASCOLA). She is also current Vice Chair of the College of American Pathologists Hemostasis/Thrombosis Committee and Treasurer of Thrombosis and Hemostasis Societies of North America (THSNA). She is a Summit Co-Chair for the Thrombosis and Hemostasis Societies of North America (THSNA) summits in 2022 and 2024 and a Meeting Co-Chair for the 2023 International Society for Laboratory Hematology (ISLH) annual meeting. She previously represented the Huntsman Cancer Institute for several years on the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines Panel for Cancer-Associated Venous Thromboembolic Disease. Dr. Smock serves on the Editorial Boards for Research and Practice in Thrombosis and Haemostasis, Seminars in Thrombosis and Haemostasis, and International Journal of Laboratory Hematology, and reviews manuscripts for many other scientific journals. She has served as a Guest Editor for Seminars in Thrombosis and Hemostasis for 4 completed or in progress themed issues related to novel analyzers and diagnostic tests in hemostasis and thrombosis. She has many clinical research interests in coagulation medicine and her work includes over 100 journal articles, book chapters, abstracts, and other publications in the fields of hemostasis/thrombosis and hematopathology.

    Specialties

    • Pathology, Clinical
    • Hematopathology
    • Pathology, Anatomical

    Board Certification

    American Board of Pathology (Anatomic & Clinical)
    American Board of Pathology (Sub: Hematology)

  • Dr. Smock is a Professor in the Department of Pathology at the University of Utah. She completed her residency and fellowship training at the University of Utah and is board certified in Anatomic and Clinical Pathology and Hematopathology. She is Vice President and Chief Medical Director for the ARUP Laboratories Institute of Clinical and Experimental Pathology (R&D), leading research and development efforts across traditional laboratory medicine, genetics, and oncology and chairing the ARUP R&D Executive Committee.

    Dr. Smock’s primary clinical responsibilities are in coagulation laboratory medicine, and she is a Medical Director of the Hemostasis/Thrombosis Laboratory at ARUP, where she enjoys being involved in all aspects of the laboratory and providing clinical consultation on difficult coagulation cases. She has additional clinical service responsibilities in hematopathology, where she signs out peripheral smears, bone marrow cases and hematology tests.

    Dr. Smock enjoys the educational aspects of academic practice and previously served as the Pathology Residency Program Director at the University of Utah. She has chaired the Clinical Competency Committees for both the residency program and hematopathology fellowship. She received the Department's Outstanding Teaching Award in Clinical Pathology in 2010, 2013, and 2017. She serves on the University of Utah Alpha Omega Alpha medical honor society (AOA) Faculty Board of Directors with an emphasis on resident, fellow, and faculty engagement. In 2018, she received the William Roberts Award for Clinical Excellence in Laboratory Medicine, and in 2022, she received the Joseph A. Knight Award for Excellence in Education, from the University of Utah Department of Pathology. In 2016, Dr. Smock was named as an American Society for Clinical Pathology 40 Under Forty honoree, recognizing her as a leader in Pathology and Laboratory Medicine.

    Dr. Smock is an active member of several professional organizations and is current President of the North American Specialized Coagulation Laboratory Association (NASCOLA). She is also current Vice Chair of the College of American Pathologists Hemostasis/Thrombosis Committee and Treasurer of Thrombosis and Hemostasis Societies of North America (THSNA). She is a Summit Co-Chair for the Thrombosis and Hemostasis Societies of North America (THSNA) summits in 2022 and 2024 and a Meeting Co-Chair for the 2023 International Society for Laboratory Hematology (ISLH) annual meeting. She previously represented the Huntsman Cancer Institute for several years on the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines Panel for Cancer-Associated Venous Thromboembolic Disease. Dr. Smock serves on the Editorial Boards for Research and Practice in Thrombosis and Haemostasis, Seminars in Thrombosis and Haemostasis, and International Journal of Laboratory Hematology, and reviews manuscripts for many other scientific journals. She has served as a Guest Editor for Seminars in Thrombosis and Hemostasis for 4 completed or in progress themed issues related to novel analyzers and diagnostic tests in hemostasis and thrombosis. She has many clinical research interests in coagulation medicine and her work includes over 100 journal articles, book chapters, abstracts, and other publications in the fields of hemostasis/thrombosis and hematopathology.

    Board Certification and Academic Information

    Academic Departments Pathology -Professor (Clinical)
    Board Certification
    American Board of Pathology (Anatomic & Clinical)
    American Board of Pathology (Sub: Hematology)

    Education history

    Fellowship Hematopathology - University of Utah School of Medicine Fellow
    Residency Pathology - University of Utah School of Medicine Resident
    Professional Medical Medicine - University of Utah M.D.
    Undergraduate Biology - Utah State University B.S.

    Selected Publications

    Journal Article

    1. Smock KJ, Moffat KA (2024). Laboratory Diagnostics for Thrombosis and Hemostasis Testing-Part 3. Semin Thromb Hemost. (Read full article)
    2. Smock KJ (2023). Von Willebrand factor testing ratios in the diagnosis and subtyping of von Willebrand disease. Int J Lab Hematol, 45 Suppl 2, 23-29. (Read full article)
    3. Smock KJ, Gosselin RC (2023). Laboratory Diagnostics for Thrombosis and Hemostasis Testing-Part II. Semin Thromb Hemost, 49(6), 569-570. (Read full article)
    4. Smock KJ, Moser KA (2023). Automation of a Factor XIII Activity Assay Utilizing a Plasma Blank Measurement. Methods Mol Biol, 2663, 693-706. (Read full article)
    5. Abou-Ismail MY, Kanack AJ, Splinter NP, Smock KJ, Moser KA, Padmanabhan A (2022). Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT. Blood Adv, 6(18), 5327-5329. (Read full article)
    6. Smock KJ, Gosselin RC (2022). Laboratory Diagnostics for Thrombosis and Hemostasis Testing-Part I. Semin Thromb Hemost, 48(6), 631-633. (Read full article)
    7. Salazar E, Long TA, Smock KJ, Wool GD, Rollins-Raval M, Chen D, Harris NS, Chan CW, Olson JD, Pham HP, Ritter J, Unold D, VanSandt AM, Goodwin Iv AJ (2022). Analysis of College of American Pathologists von Willebrand Factor Proficiency Testing Program. Semin Thromb Hemost, 48(6), 690-699. (Read full article)
    8. Kanack AJ, Bayas A, George G, Abou-Ismail MY, Singh B, Kohlhagen MC, Splinter NP, Christ M, Naumann M, Moser KA, Smock KJ, Grazioli A, Wen R, Wang D, Murray DL, Padmanabhan A (2021). Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT. Blood, 140(1), 73-77. (Read full article)
    9. Kanack AJ, Singh B, George G, Gundabolu K, Koepsell SA, Abou-Ismail MY, Moser KA, Smock KJ, Green D, Major A, Chan CW, Wool GD, Reding M, Ashrani AA, Bayas A, Grill DE, Padmanabhan A (2022). Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. Am J Hematol, 97(5), 519-526. (Read full article)
    10. Pikta M, Vasse M, Smock KJ, Moser KA, van DM, Lejniece S, Szanto T, Bautista H, Nouadje G, Banys V (2021). Establishing reference intervals for von Willebrand factor multimers. J Med Biochem, 41(1), 115-121. (Read full article)
    11. Volod O, Brown AF, Chandler WL, Goodwin AJ, Harris NS, Higgins RA, Ison JA, Moser KA, Olson JD, Pham HP, Ravindran A, Rollins-Raval M, Salazar E, Unold D, Smock KJ, VanSandt A, Wool G, Long T, Chen D (2022). Interlaboratory performance in measurement of dabigtran and rivaroxaban: Results of the College of American Pathologists external quality assessment program. Arch Pathol Lab Med, 146(2), 145-153.
    12. Smock KJ, Moser KA (2021). Cryptogenic oozers and bruisers. Hematology Am Soc Hematol Educ Program, 2021(1), 85-91. (Read full article)
    13. Moser KA, Smock KJ (2021). Direct oral anticoagulant (DOAC) interference in hemostasis assays. Hematology Am Soc Hematol Educ Program, 2021(1), 129-133. (Read full article)
    14. Smock KJ (2021). ADAMTS13 testing update: Focus on laboratory aspects of difficult thrombotic thrombocytopenic purpura diagnoses and effects of new therapies. Int J Lab Hematol, 43 Suppl 1, 103-108. (Read full article)
    15. Carter-Febres M, Smock KJ, Ware AL, Afify Z (2021). Improvement of bleeding manifestations of acquired von Willebrand syndrome after balloon aortic valvuloplasty in a child with aortic stenosis. Prog Pediatr Cardiol, 60, 101334.
    16. Moyer AM, McMillin GA, Long TA, Gandhi MJ, Mao R, Smock KJ, Halley JG, Weck KE (2020). Genotype and Phenotype Concordance for Pharmacogenetic Tests Through Proficiency Survey Testing. Arch Pathol Lab Med, 144(9), 1057-1066. (Read full article)
    17. Hayward CPM, George TI, Van Cott EM, Smock KJ (2020). Patient advocacy and its importance to laboratory medicine practice. Int J Lab Hematol, 42 Suppl 1, 21-22. (Read full article)
    18. Liederman Z, Van Cott EM, Smock K, Meijer P, Selby R (2019). Heparin-induced thrombocytopenia: An international assessment of the quality of laboratory testing. J Thromb Haemost, 17(12), 2123-2130. (Read full article)
    19. Smock KJ, Moser KA (2018). What have we learned from coagulation laboratory participation in external quality programs? Int J Lab Hematol, 41 Suppl 1, 49-55. (Read full article)
    20. Chandler WL, Brown AF, Chen D, Moser K, Olson JD, Pham HP, Smock KJ, Volod O, Higgins RA (2018). External Quality Assurance of Platelet Function Assays: Results of the College of American Pathologists Proficiency Testing Program. Arch Pathol Lab Med, 143(4), 472-482. (Read full article)
    21. Khan J, Schmidt RL, Spittal MJ, Goldstein Z, Smock KJ, Greene DN (2019). Venous Thrombotic Risk in Transgender Women Undergoing Estrogen Therapy: A Systematic Review and Metaanalysis. Clin Chem, 65(1), 57-66. (Read full article)
    22. Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Gundabolu K, Hendrie P, Lee AI, Lee JT, Mann J, McMahon B, Millenson MM, Morton C, Ortel TL, Ozair S, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang TF, Williams E, Zakarija A, Hammond L, Dwyer MA, Engh AM (2018). NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw, 16(11), 1289-1303. (Read full article)
    23. Crist RA, Heikal NM, Rodgers GM, Grenache DG, Smock KJ (2018). Evaluation of a new commercial method for von Willebrand factor multimeric analysis. Int J Lab Hematol, 40(5), 586-591.
    24. Gangaraju R, Rets A, Smock KJ, Heikal NM (2017). Rare complication of treated immune thrombocytopenia. Am J Hematol, 92(11), 1262-1266. (Read full article)
    25. Rudolf J, Jackson BR, Wilson AR, Smock KJ, Schmidt RL (2017). Organizational Benchmarks for Test Utilization Performance: An Example Based on Positivity Rates for Genetic Tests. Am J Clin Pathol, 147(4), 382-389. (Read full article)
    26. Goodwin AJ, Higgins RA, Moser KA, Smock KJ, Chandler WL, Kottke-Marchant K, Hartman SK, Volod O, Brown AF, Johari VP, Burr S, Polyakov N, Chen D (2016). Issues Surrounding Age-Adjusted d-Dimer Cutoffs That Practicing Physicians Need to Know When Evaluating Patients With Suspected Pulmonary Embolism. Ann Intern Med, 166(5), 361-363. (Read full article)
    27. Schmidt RL, Chute DJ, Colbert-Getz JM, Firpo-Betancourt A, James DS, Karp KJ, Miller DC, Milner DA, Smock KJ, Sutton AT, Walker BS, White KL, Wilson AR, Wojcik EM, Yared MA, Factor RE (2017). Statistical Literacy Among Academic Pathologists: A Survey Study to Gauge Knowledge of Frequently Used Statistical Tests Among Trainees and Faculty. Arch Pathol Lab Med, 141(2), 279-287.
    28. Van Cott EM, Smock KJ, Chen D, Hsu P, Zantek ND, Meijer P (2016). Testing for dabigatran and rivaroxaban by clinical laboratories. Am J Hematol, 91(11), E464-E467. (Read full article)
    29. Zantek ND, Hayward CP, Simcox TG, Smock KJ, Hsu P, Van Cott EM (2016). An Assessment of the State of Current Practice in Coagulation Laboratories. Am J Clin Pathol, 146(3), 378-83. (Read full article)
    30. Smock KJ, Plumhoff EA, Meijer P, Hsu P, Zantek ND, Heikal NM, Van Cott EM (2016). Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American Specialized Coagulation Laboratories. Thromb Haemost, 116(1), 50-7. (Read full article)
    31. Smock KJ (2016). The role of ADAMTS13 testing in the work-up of patients with suspected thrombotic thrombocytopenic purpura. Clinical Laboratory News, 42(4), 10-14.
    32. Sono-Koree N, Crist RA, Heikal NM, Rodgers GM, Smock KJ (2016). A high-performance liquid chromatography method for the serotonin release assay is equivalent to the radioactive method. Int J Lab Hematol, 38(1), 72-80.
    33. Staddon JH, Smock KJ, Schiffman JD, Fluchel MN, Engel ME, Weyrich AS, Campbell RA (2015). Pegasparaginase treatment alters thrombin generation by modulating the protein C and S system in acute lymphoblastic leukaemia/lymphoma. Blood Coagul Fibrinolysis, 26(7), 840-3.
    34. Streiff MB, Holmstrom B, Ashrani A, Bockenstedt PL, Chesney C, Eby C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Hendrie P, Kuderer N, Lee A, Lee JT, Lovrincevic M, Millenson MM, Neff AT, Ortel TL, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang TF, Yee GC, Zakarija A, McMillian N, Engh AM (2015). Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. J Natl Compr Canc Netw, 13(9), 1079-95. (Read full article)
    35. Desai DS, Lyon E, Rodgers GM, Jama MA, Wallentine SL, Smock KJ (2015). Elderly female with a personal and family history of a bleeding disorder. Clin Chem, 61(7), 909-12. (Read full article)
    36. Zantek ND, Hsu P, Meijer P, Smock KJ, Plumhoff EA, Refaai MA, Van Cott EM (2015). Quality of factor XI activity testing in North American Specialized Coagulation Laboratories. Int J Lab Hematol, 37 Suppl 1, 99-107. (Read full article)
    37. Smock KJ, Perkins SL (2014). Thrombocytopenia: an update. Int J Lab Hematol, 36(3), 269-78. (Read full article)
    38. Smock KJ, Schmidt RL, Hadlock G, Stoddard G, Grainger D, Munger MA (2014). Assessment of orally-dosed commercial silver nanoparticles on human ex vivo platelet aggregation. Nanotoxicology, 8(3), 328-33.
    39. Smock KJ, Agarwal AM, Lim MS, Tripp SR, Miles RR, Patel JL, Abromowitch M, Lones MA, Cairo MS, Perkins SL (2014). Expression of Notch1 and mTOR Pathway Proteins in Pediatric Lymphoblastic Lymphoma; A Children’s Oncology Group Report. J Hematop, 7(1), 9-14.
    40. Smock KJ, Ledford-Kraemer MR, Meijer P, Hsu P, Van Cott EM (2014). Proficiency testing results for heparin-induced thrombocytopenia in north america. Semin Thromb Hemost, 40(2), 254-60. (Read full article)
    41. Hsu P, Zantek ND, Meijer P, Hayward CP, Brody J, Zhang X, Smock KJ, Van Cott EM (2014). Factor XIII Assays and associated problems for laboratory diagnosis of factor XIII deficiency: an analysis of International Proficiency testing results. Semin Thromb Hemost, 40(2), 232-8. (Read full article)
    42. Heikal NM, Murphy KK, Crist RA, Wilson AR, Rodgers GM, Smock KJ (2013). Elevated factor IX activity is associated with an increased odds ratio for both arterial and venous thrombotic events. Am J Clin Pathol, 140(5), 680-5. (Read full article)
    43. Heikal NM, Smock KJ (2013). Laboratory testing for platelet antibodies. Am J Hematol, 88(9), 818-21.
    44. Pandey S, Post SR, Alapat DV, Smock KJ, Post GR (2013). Prolonged prothrombin time correlates with serum immunoglobulin levels in patients with plasma cell dyscrasia. Int J Lab Hematol, 35, 421-27.
    45. Shirts BH, Rodgers GM, Smock KJ (2012). Prothrombin time, activated partial thromboplastin time and dilute Russell's Viper Venom times are not shorter in patients with the prothrombin G20210A mutation, and dilute Russell's Viper Venom time may be longer. Thromb Res, 130(3), e134-8.
    46. Tantravahi SK, Williams LB, Digre KB, Creel DJ, Smock KJ, DeAngelis MM, Clayton FC, Vitale AT, Rodgers GM (2012). An inherited disorder with splenomegaly, cytopenias, and vision loss. Am J Med Genet A, 158A(3), 475-81. (Read full article)
    47. Sangle NA, Agarwal AM, Smock KJ, Leavitt MO, Warnke R, Bahler D, Perkins SL (2011). Diffuse large B-cell lymphoma with aberrant expression of the T-cell antigens CD2 and CD7. Appl Immunohistochem Mol Morphol, 19(6), 579-83.
    48. Smock KJ, Saunders PJ, Rodgers GM, Johari V (2011). Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods. Am J Hematol, 86(12), 1032-34.
    49. Sangle NA, Smock KJ (2011). Antiphospholipid antibody syndrome. Arch Pathol Lab Med, 135(9), 1092-6. (Read full article)
    50. Wilcox R, Pendleton RC, Smock KJ, Rodgers GM (2011). Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice. Hosp Pract (1995), 39(3), 23-34. (Read full article)
    51. Sangle NA, Rodgers GM, Smock KJ (2011). Prevalence of heparin in samples submitted for lupus anticoagulant testing. Lab Hematol, 17(1), 6-11. (Read full article)
    52. Smock KJ, Rodgers GM (2010). Laboratory evaluation of aspirin responsiveness. Am J Hematol, 85(5), 358-60.
    53. Penmetsa GK, Rodgers GM, Smock KJ (2010). Avoiding errors in the laboratory evaluation of potent lupus anticoagulants. Am J Hematol, 85(4), 272-4. (Read full article)
    54. Smock KJ, Crist RA, Hansen SJ, Rodgers GM, Lehman CM (2010). Discard tubes are not necessary when drawing samples for specialized coagulation testing. Blood Coagul Fibrinolysis, 21(3), 279-82. (Read full article)
    55. Smock KJ, Rodgers GM (2009). Laboratory identification of lupus anticoagulants. Am J Hematol, 84(7), 440-2. (Read full article)
    56. Crist RA, Gibbs K, Rodgers GM, Smock KJ (2009). Effects of EDTA on routine and specialized coagulation testing and an easy method to distinguish EDTA-treated from citrated plasma samples. Lab Hematol, 15(4), 45-8. (Read full article)
    57. Smock KJ, Nelson M, Tripp SR, Sanger WG, Abromowitch M, Cairo MS, Perkins SL, Childrens Oncology Group (2008). Characterization of childhood precursor T-lymphoblastic lymphoma by immunophenotyping and fluorescent in situ hybridization: a report from the Children's Oncology Group. Pediatr Blood Cancer, 51(4), 489-94. (Read full article)
    58. Smock KJ, Yaish HM, Cairo MS, Lones MA, Willmore-Payne C, Perkins SL (2007). Mantle cell lymphoma presenting with unusual morphology in an adolescent female: a case report and review of the literature. Pediatr Dev Pathol, 10(5), 403-8. (Read full article)
    59. Smock KJ, Perkins SL, Bahler DW (2007). Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment. Arch Pathol Lab Med, 131(6), 951-5. (Read full article)
    60. Raetz EA, Perkins SL, Bhojwani D, Smock K, Philip M, Carroll WL, Min DJ (2006). Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer, 47(2), 130-40. (Read full article)
    61. Herron MD, Vanderhooft SL, Smock K, Zhou H, Leachman SA, Coffin C (2004). Proliferative nodules in congenital melanocytic nevi: a clinicopathologic and immunohistochemical analysis. Am J Surg Pathol, 28(8), 1017-25. (Read full article)

    Book Chapter

    1. Smock KJ (2024). Coagulation Laboratory Testing. In Raval J and Rollins-Raval M (Eds.), AABB Hemostasis/Thrombosis Handbook. AABB.
    2. Smock KJ, Volod O (2023). Viscoelastic Testing and Bleeding Disorders (Chapter 12). In Volod O (Ed.), Whole Blood Viscoelastic Assays (VEA) in Clinical Diagnosis. An Illustrated Case-Based Guide (1). Chicago, IL: CAP Press.
    3. Smock KJ (2023). Examination of the Blood and Bone Marrow. In Means, Arber, Glader, Appelbaum, Rodgers, Dispenzieri, Fehniger, Michaelis, Leonard (Eds.), Wintrobe's Clinical Hematology (15). Wolters Kluwer.
    4. Smock KJ, Friedman KD (2022). Laboratory Hematology (Chapter 12). In Altman JK, Mandernach MW, Naik RP, Ulrickson M (Eds.), American Society of Hematology Self-Assessment Program (ASH-SAP) (8). Washington, DC: American Society of Hematology.
    5. Smock KJ (2018). Examination of the Blood and Bone Marrow. In Greer, Appelbaum, Arber, Dispenzieri, Fehniger, Glader, List, Means, Rodgers (Eds.), Wintrobe's Clinical Hematology (14). Philadelphia: Wolters Kluwer.
    6. Smock KJ, Heikal NM (2015). Laboratory Assays for ADAMTS-13. In Rodgers GM (Ed.), ADAMTS-13 Biology and Disease (1). New York City: Springer.
    7. Smock KJ (2015). Pharmacogenetic Testing for Anticoagulant and Antiplatelet therapies. In Bennett ST, Lehman CM, Rodgers GM (Eds.), Laboratory Hemostasis (2). New York City: Springer.
    8. Smock KJ, Perkins SL (2013). Examination of the Blood and Bone Marrow. In Greer, Arber, Glader, List, Means, Paraskevas, Rodgers (Eds.), Wintrobe's Clinical Hematology (13). Philadelphia: Lippincott Williams & Wilkins.

    Editorial

    1. Pruthi RK, Smock K, Hayward CPM (2022). Memorial notice: William L. Nichols, MD. Int J Lab Hematol, 45(2), 139-140. (Read full article)
    2. Van Cott EM, Smock KJ, Lippi G (2019). Innovations in Thrombosis and Hemostasis: A Glimpse Toward the Future of Diagnostic Analyzers. Sem Thromb Haemost, 45(3), 225-227.

    Letter

    1. Abou-Ismail MY, Moser KA, Smock KJ, Lim MY (2021). Vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism. [Letter to the editor]. Am J Hematol, 96(9), E346-E349. (Read full article)
    2. Mathew Thomas V, Gilreath JA, Newton S, Smock KJ, Lim MY (2021). Daratumumab as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. [Letter to the editor]. Haemophilia, 27(4), e563-e566. (Read full article)
    3. Moser KA, Pearson LN, Pelt CE, Olson JD, Goodwin AJ, Isom JA, Harris NS, Pham HP, Smock KJ, Unold D, VanSandt AM, Volod O, Chen D (2020). Letter to the Editor on "The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria". [Letter to the editor]. J Arthroplasty, 35(9), 2682-2683. (Read full article)

    Abstract

    1. Knoebl P, Sanchez-Lucertos A, Scully M, Sathar J, Veyradier A, Mancini I, Fretwell R, Cuker A, Smock K, Meijer P, Binder NB, Peyvandi F, Zheng L, Haberichter S, Vanhooreelbeke K, Kremer-Hovinga JA (2023). Knoebl P, Sanchez-Lucertos A, Scully M, Sathar J, Veyradier A, Mancini I, Fretwell R, Cuker A, Smock K, Meijer P, Binder NB, Peyvandi F, Zheng L, Haberichter S, Vanhooreelbeke K, Kremer-Hovinga JA.  Towards the standrdisation of ADAMTS-13antibody testing in thrombotic thrombocytopenic purpura (TTP)- results of the IMATAS collaborative study (PB0313) [Abstract]. 7(S2), 806 of 1126.
    2. Moser KA, Lim MY, Smock KJ (2023). Pathologist-driven reflexive evaluation of prolonged clotting times:  A national reference laboratory experience [Abstract]. 98(S1), E1-E128.
    3. Jennings I, Meijer P, Arunachalam S, Olson J, Marlar RA, Zantek N, Bon C, Dean E, Bon C, Dean E, van Essen-Hollestelle MJ, Kutsch M, Meley R, Plumhoff E, Salazar E, Smock K, Spannagl M, Reilly-Stitt C, Unold D, Walker ID (2023). Comparison of thrombophilia assay results for the ISTH/SSC Plasma Standard from different EQA providers – data from the EQATH group [Abstract]. 7(S2), 1-1126.
    4. Crist RA, Stephens DA, Rodgers GM, Moser KA, Smock KJ (2023). Effect of three factor Xa inhibitors on common coagulation assays             [Abstract]. 98(S1), E1-E128.
    5. Padmanabhan A, Kanack A, Singh B, George G, Gundabolu K, Koepsell S, Abou-Ismail Y, Moser K, Smock K, Green D, Major A, Chan C, Wool G, Reding M, Ashrani A, Bayas A, Grill D (2022). Persistence of Ad26.COV2.S-associated VITT and specific detection of VITT antibodies [Abstract]. 6(S1), e12787.
    6. Singh B, Kanack A, Bayas A, George G, Abou-Ismail MY, Kohlhagen M, Christ M, Naumann M, Moser K, Smock K, Grazioli A, Murray D, Padmanabhan A (2021). Monoclonal and oligoclonal anti-PF4 antibodies mediate VITT [Abstract]. 138(S1), 3220.
    7. Stephens DA, Crist RA, Rodgers GM, Smock KJ, Moser KA (2021). A National Reference Laboratory’s Review of Test Ordering Patterns and Positivity Rates During the COVID-19 Pandemic [Abstract].
    8. Crist RA, Stephens DA, Rodgers GM, Corean J, Moser KA, Smock KJ (2020). Performance characteristics of a chromogenic factor VIII method on the STA-R Evolution XP [Abstract].
    9. Stephens DA, Crist RA, Rodgers GM, Smock KJ, Moser KA (2020). Stephens DA, Crist RA, Rodgers GM, Smock KJ, Moser KA.  Retrospective analysis of ten years of PT and aPTT validation data in a reference lab.    [Abstract].
    10. Pikta M, Vasse M, Lejniece, Smock KJ, Moser KA, Bautista H, Nouadje G, Banys V (2020). Establishing reference intervals for von Willebrand factor multimer fractions. [Abstract].
    11. Crist RA, Rodgers GM, Smock KJ, Moser KA (2019). Real world results from an ADAMTS13 reflexive panel performed in a reference laboratory [Abstract]. 41(S2), 1-205.
    12. Crist RA, Smock KJ, Rodgers GM, Heikal NM (2018). A correlation study of ADAMTS13 neutralizing and non-neutralizing antibodies [Abstract]. Am J Hematol, 93(9), E253-328.
    13. Liederman Z, Van Cott EM, Smock KJ, Meijer P, Selby R (2018). Heparin-induced thrombocytopenia: An international assessment of the quality of laboratory testing [Abstract]. Res Pract Thromb Haemost, 2(S1), 1-368, #PB570.
    14. Crist RA, Heikal NM, Rodgers GM, Grenache DG, Kunzler TM, Choi MA, Smock KJ (2017). Evaluation of a New Commercial Method for von Willebrand Factor Multimeric Analysis [Abstract]. Int J Lab Hematology, 39(S2), 31.
    15. Rudolf J, Smock K, Jackson B, Schmidt R (2016). Benchmarking utilization with population prevalence data: A novel use of national census data [Abstract]. J Pathol Inform, 7, 33.
    16. Crist RA, Heikal NM, Rodgers GM, Smock KJ (2016). Avoiding underestimation of protein S activity in APC resistant specimens [Abstract]. Am J Hematol, 91(9), E363-430, #T19.
    17. Nance D, Campbell RA, Rowley JW, Downie JM, Jorde LB, Kahr WH, Smock KJ, Mereby SA, Manne BK, Tolley ND, Zimmerman GA, Weyrich AS, Rondina MT (2016). Combined variants in factor VIII and PTGS-1 amplify hemorrhage severity across three generations of descendants [Abstract]. Am J Hematol, 91(9), E363-430, #4.
    18. Heikal NM, Crist RA, Rodgers GM, Smock KJ (2015). The serotonin release assay should be the first-line test for heparin-induced thrombocytopenia in patients with antiphospholipid antibodies [Abstract]. Int J Lab Hematol, 37(Supp 2), 1-130, #214.
    19. Crist RA, Sono-Koree N, Heikal NM, Rodgers GM, Smock KJ (2015). Automation of a factor XIII activity assay utilizing a plasma blank improves the quantitation of factor XIII activity [Abstract]. Int J Lab Hematol, 37(Supp 2), 1-130, #201.
    20. Sono-Koree N, Crist RA, Heikal NM, Rodgers GM, Smock KJ (2015). A high-performance liquid chromatography method for the serotonin release assay is equivalent to the radioactive method [Abstract]. Int J Lab Hematol, 2015(Supp 2), 1-130, #24.
    21. Staddon J, Smock K, Schiffman J, Engel M, Fluchel M, Weyrich A (2014). Pegasparaginase treatment in pediatric acute lymphoblastic malignancy alters thrombin generation through modulation of the protein C and S system [Abstract]. Pediatr Blood Cancer, 61(S1), S1-104.

    Other

    1. National Comprehensive Cancer Network NCCN Guidelines Panel Members, Cancer-Associated Venous Thromboembolic Disease Streiff MB, Holmstrom B, Angelini D, Ashrani A, Elshoury A, Fanikos J, Kleber YF, Fogerty AE, Gao S, Goldhaber S, Gundabolu K, Lake L, Leavitt AD, Lee A, Lee JT, Mann J, McMahon B, Morton C, Ortel TL, Paschal R, Schaefer J, Shattil S, Siddiqi T, Smock KJ, Soff G, Sudheendra D, Wang TF, Williams E, Zakarija A (2015-2020). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Cancer-Associated Venous Thromboembolic Disease. NCCN.org (Contributed to Versions 1.2015, 1.2016, 1.2017, 1.2018, 1.2019, 1.2020 (2020 members shown above)).
    2. Tebo AE, Smock KJ, Branch WD (2011). Laboratory diagnostic assays for antiphospholipid syndrome. American Society for Clinical Pathology (ASCP) CheckSample Series- Clinical Chemistry (51(3)).